13F-HR/A filed by ACORN CAPITAL ADVISORS, LLC
ACORN CAPITAL ADVISORS, LLC filed this 13F-HR/A for the quarter ended 2024-12-31, filed 2025-05-19, with 21 holding rows worth $185,821,131.
- Accession
- 0001636587-25-000020
- Filer
- CIK 2054410
- Filed
- 2025-05-19
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2024
A holdings report, amendment of type restatement, 21 entries on the cover page, a total value of $185,821,131 stated on the cover page (in dollars after the unit check, H1), rows summing to $185,821,131 with VALUE read as dollars as filed, 13F file number 028-25253. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 1,131,501 | $32,451,449 | dollars as filed | |
| Y-mAbs Therapeutics Inc | 984241109 | Common Stock | 2,861,825 | $22,408,090 | dollars as filed | |
| CANDEL THERAPEUTICS INC | 137404109 | COMMON STOCK | 1,939,644 | $16,836,110 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 1,516,303 | $16,148,627 | dollars as filed | |
| PUMA BIOTECHNOLOGY INC | 74587V107 | COMMON STOCK | 3,940,052 | $12,017,158 | dollars as filed | |
| BICARA THERAPEUTICS INC | 055477103 | COM | 643,381 | $11,207,697 | dollars as filed | |
| TERNS PHARMACEUTICALS INC COM | 880881107 | Stock | 1,971,264 | $10,920,802 | dollars as filed | |
| ONKURE THERAPEUTICS INC | 68277Q105 | COM CL A | 1,439,674 | $10,247,562 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 2,001,048 | $8,244,318 | dollars as filed | |
| PROTARA THERAPEUTICS INC | 74365U107 | COM STK | 1,279,800 | $6,757,344 | dollars as filed | |
| CYBIN INC | 23256X407 | COM NEW | 734,393 | $6,477,346 | dollars as filed | |
| CARDIFF ONCOLOGY INC | 14147L108 | COM | 1,442,308 | $6,259,617 | dollars as filed | |
| X4 Pharmaceuticals, Inc. | 98420X103 | COM | 7,310,650 | $5,363,093 | dollars as filed | |
| MURAL ONCOLOGY PUB LTD CO | G63365103 | ORD SHS | 1,286,079 | $4,141,174 | dollars as filed | |
| WHITEHAWK THERAPEUTICS INC | 00032Q104 | CMN | 1,147,052 | $3,618,950 | dollars as filed | |
| OPTINOSE INC | 68404V209 | COM | 422,813 | $2,824,391 | dollars as filed | |
| Q32 BIO INC | 746964105 | Common Stock | 803,425 | $2,763,782 | dollars as filed | |
| ACRIVON THERAPEUTICS INC | 004890109 | CMN | 405,237 | $2,439,527 | dollars as filed | |
| BIOATLA INC | 09077B104 | COM | 4,032,046 | $2,383,746 | dollars as filed | |
| VYNE THERAPEUTICS INC | 92941V308 | COM | 456,970 | $1,530,850 | dollars as filed | |
| VERASTEM INC | 92337C203 | COMMON STOCK | 779,498 | $779,498 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001636587-25-000009 | superseded | 2025-02-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001636587-25-000016 | superseded | 2025-05-07 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001636587-25-000020 | this filing | 2025-05-19 | acceptance time not in the bulk data set |